FastWave Medical Earns 'Fierce 15' Recognition While Securing Eighth U.S. Patent For IVL Portfolio

Both milestones come on the heels of FastWave's first-in-human study of its Sola™coronary IVL system.

MINNEAPOLIS, July 15, 2025 /PRNewswire/ -- FastWave Medical, a pioneering intravascular lithotripsy (IVL) startup, has been honored with inclusion in Fierce Medtech's 2024 "Fierce 15," an annual list that recognizes the most promising private medtech companies. The honor comes as FastWave secures its eighth U.S. patent for its electric IVL (E-IVL) platform, Artero™, reflecting the company's continued innovation in developing next-generation solutions for peripheral artery disease treatment. 

The Fierce 15 celebrates the spirit of being "fierce" — championing innovation and creativity in the face of intense competition. Now in its ninth year, this prestigious annual selection spotlights companies showing exceptional execution and the potential to raise the standard of care. FastWave's early traction, growing patent portfolio, and physician-centered product design helped earn this year's distinction.

"IVL has become one of my frontline tools for treating peripheral artery disease—it's one of the most exciting breakthroughs we've seen in years," said Dr. Constantino Pena, diagnostic and interventional radiologist at Baptist Health South Florida. "Watching companies like FastWave push the envelope and bring fresh ideas to IVL technology makes this an incredible time to be in the field. The pace of innovation is truly inspiring, and it's patients who stand to benefit most."

Since its founding in 2021, FastWave has advanced a dual-platform approach to IVL, developing tools that address the limitations of legacy technology. Its Artero™ system is designed to streamline peripheral artery disease treatment with a simplified interface that delivers circumferential sonic pressure waves at 4 Hz—twice the speed of existing IVL devices. Hands-free operation, real-time feedback, and a reduced crossing profile enable efficient use in complex anatomy while delivering consistent, predictable therapeutic energy for modifying calcium.

"Too many medical devices are designed behind closed doors with limited user feedback. We wanted to flip that around and start with the daily frustrations physicians face and build from there," said Scott Nelson, co-founder and CEO of FastWave Medical. "This achievement as a Fierce 15 company isn't just validation. It's fuel to accelerate what's next."

The recognition comes as FastWave advances on multiple fronts, including successful first-in-human procedures for Sola™, its laser-based coronary IVL system, as part of an ongoing global feasibility study.

About FastWave Medical

FastWave Medical pioneers next-generation intravascular lithotripsy (IVL) technology to transform the treatment of calcific artery disease in peripheral and coronary applications. Founded by industry veterans with deep startup and multinational device experience, FastWave has secured over $40 million in venture funding to advance its dual-platform IVL systems.

The company's technologies address limitations in current calcium-modification devices by improving deliverability, energy output, and usability—eliminating extra steps while maintaining the simplicity and safety that have driven IVL's rapid adoption. Learn more at https://fastwavemedical.com.

Medical Contact
FastWave Medical
(833) 888-9283
[email protected]

SOURCE FastWave Medical